Evidence map›Paper›PMID 39660217›Full record

ArticleComputational and structural biotechnology journal2024

Xiaohu Hao, Dongping Liu, Long Fan

Abstract read
In one paragraph

Article in Computational and structural biotechnology journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Xiaohu HaoProduction and R&D Center I of LSS (Life Science Service), GenScript Biotech Corporation, No. 28, Yongxi Rd., Nanjing, 211100, Jiangsu, China.
Dongping LiuProduction and R&D Center I of LSS (Life Science Service), GenScript Biotech Corporation, No. 28, Yongxi Rd., Nanjing, 211100, Jiangsu, China.
Long FanProduction and R&D Center I of LSS (Life Science Service), GenScript Biotech Corporation, No. 28, Yongxi Rd., Nanjing, 211100, Jiangsu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The application of antibody therapeutics is promising in the field of immunotherapy. While, heterologization should be done in most cases before applying the therapeutic antibodies into bodies, e.g., humanization, caninization and felinization for human beings, canine and feline, respectively. Here we report YabXnization, the platform which realizes antibody heterologization on the basis of rational design and artificial intelligence (AI)-assisted computation. YabXnization provides two ways for heterologization: traditional CDR-grafting and backmutation-based rational design; and AI-assisted fusion computational design. Taking humanization as example, both of the two ways first find the proper template for heavy and light chains with CDR-grafting followed. For rational design, bioinformatics analysis-based backmutation is then conducted. For AI-assisted computational design, the backmutation and humanness evaluation are implemented through evolutionary computation framework with DeepForest-based humanness evaluation model and the distance to the previously found human template as objective functions. Finally, the top

Indexed as

CaninizationDeepForestFelienizationHumanizationMonoclonal antibody

Identifiers

PMID39660217
PMCPMC11630649

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.